S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
NASDAQ:DBVT

DBV Technologies (DBVT) Stock Price, News & Analysis

$0.74
-0.03 (-4.13%)
(As of 12:56 PM ET)
Today's Range
$0.72
$0.76
50-Day Range
$0.76
$0.92
52-Week Range
$0.65
$2.37
Volume
13,873 shs
Average Volume
50,678 shs
Market Capitalization
$141.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

DBV Technologies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
566.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of DBV Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1,624 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.42 out of 5 stars

Medical Sector

323rd out of 939 stocks

Biological Products, Except Diagnostic Industry

46th out of 154 stocks

DBVT stock logo

About DBV Technologies Stock (NASDAQ:DBVT)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBVT Stock Price History

DBVT Stock News Headlines

DBVT DBV Technologies S.A.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)
DBV Technologies S.A. ADR
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DBVT
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+580.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-72,730,000.00
Net Margins
-461.32%
Pretax Margin
-462.35%

Debt

Sales & Book Value

Annual Sales
$15.73 million
Book Value
$0.73 per share

Miscellaneous

Free Float
191,495,000
Market Cap
$141.75 million
Optionable
Optionable
Beta
0.76
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Daniel Tassé (Age 64)
    CEO & Director
    Comp: $1.21M
  • Dr. Pharis Mohideen (Age 59)
    Chief Medical Officer
    Comp: $725.12k
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)
    CFO & Principal Accounting Officer
  • Dr. Kevin P. Malobisky M.S.
    Ph.D., R.A.C., Chief Operations Officer
  • Ms. Michele F. Robertson
    Chief Legal Officer
  • Ms. Caroline Daniere (Age 49)
    Chief Human Resources Officer & Chief of Staff
  • Dr. Wence Agbotounou
    Chief Clinical Trial Officer & Senior VP
  • Mr. Edward P. Jordan M.B.A. (Age 56)
    Senior Vice President of Commercial Operations North America
  • Alan Kerr
    Senior VP & Head of Global Regulatory Affairs
  • Mr. Pascal Wotling
    Chief External Manufacturing & Supply Chain Officer

DBVT Stock Analysis - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares.
View DBVT analyst ratings
or view top-rated stocks.

What is DBV Technologies' stock price target for 2024?

3 equities research analysts have issued 1 year price objectives for DBV Technologies' stock. Their DBVT share price targets range from $1.00 to $10.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price.
View analysts price targets for DBVT
or view top-rated stocks among Wall Street analysts.

How have DBVT shares performed in 2024?

DBV Technologies' stock was trading at $0.9528 on January 1st, 2024. Since then, DBVT shares have decreased by 21.3% and is now trading at $0.75.
View the best growth stocks for 2024 here
.

Are investors shorting DBV Technologies?

DBV Technologies saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 548,100 shares, a drop of 6.2% from the February 29th total of 584,500 shares. Based on an average daily volume of 67,900 shares, the days-to-cover ratio is currently 8.1 days.
View DBV Technologies' Short Interest
.

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our DBVT earnings forecast
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) posted its earnings results on Thursday, March, 7th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.10. The business earned $8.88 million during the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative trailing twelve-month return on equity of 46.33%. During the same period in the previous year, the company earned ($0.23) earnings per share.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

Who are DBV Technologies' major shareholders?

DBV Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Braidwell LP (4.07%), Boxer Capital LLC (0.26%), Citadel Advisors LLC (0.08%), Cowen AND Company LLC (0.03%), Goldman Sachs Group Inc. (0.02%) and Goldman Sachs Group Inc. (0.02%). Insiders that own company stock include Adora Ndu, Daniel B Soland, Pharis Mohideen and Timothy E Morris.
View institutional ownership trends
.

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DBVT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners